Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Down 5.7 %

Shares of BCLI stock opened at $0.27 on Friday. The stock has a market capitalization of $18.64 million, a P/E ratio of -0.83 and a beta of 0.35. The firm’s 50 day moving average is $0.33 and its 200 day moving average is $0.42. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $1.08.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the previous year, the firm posted ($0.27) EPS. As a group, equities analysts predict that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.